1
|
Patel M, Kothari C. Critical review of statins: A bio-analytical perspective for therapeutic drug monitoring. Trends Analyt Chem 2017. [DOI: 10.1016/j.trac.2016.10.011] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
|
2
|
Al-Badr AA, Mostafa GAE. Pravastatin sodium. PROFILES OF DRUG SUBSTANCES, EXCIPIENTS, AND RELATED METHODOLOGY 2014; 39:433-513. [PMID: 24794911 DOI: 10.1016/b978-0-12-800173-8.00008-8] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/16/2023]
Abstract
Pravastatin sodium is an [HMG-CoA] reductase inhibitor and is a lipid-regulating drug. This monograph includes the description of the drug: nomenclature, formulae, elemental composition, solubility, appearance, and partition coefficient. The uses and the methods that have been reported for the synthesis of this drug are described. The physical methods that were used to characterize the drug are the X-ray powder diffraction pattern, thermal methods, melting point, and differential scanning calorimetry. This chapter also contains the following spectra of the drug: the ultraviolet spectrum, the vibrational spectrum, the nuclear magnetic resonance spectra, and the mass spectrum. The compendial methods of analysis include the British Pharmacopoeia and the United States Pharmacopoeia methods. Other methods of analysis that are included in this profile are spectrophotometric, electrochemical, polarographic, voltammetric and chromatographic, and immunoassay methods. The chapter also contains the pharmacokinetics, metabolism, stability, and articles that reviewed pravastatin sodium manufacturing, characterization, and analysis. One hundred and sixty-two references are listed at the end of this comprehensive profile.
Collapse
Affiliation(s)
- Abdullah A Al-Badr
- Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh, Kingdom of Saudi Arabia
| | - Gamal A E Mostafa
- Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh, Kingdom of Saudi Arabia
| |
Collapse
|
3
|
Ashour S, Khateeb M. Kinetic spectrophotometric determination of pravastatin in drug formulations via derivatization with 4-chloro-7-nitrobenzo-2-oxa-1,3-diazole (NBD-Cl). ARAB J CHEM 2011. [DOI: 10.1016/j.arabjc.2010.06.050] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
4
|
Mertens B, Cahay B, Klinkenberg R, Streel B. An automated method for the simultaneous determination of pravastatin, 3-hydroxy isomeric metabolite, pravalactone and fenofibric acid in human plasma by sensitive liquid chromatography combined with diode array and tandem mass spectrometry detection. J Chromatogr A 2008; 1189:493-502. [DOI: 10.1016/j.chroma.2008.01.060] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2007] [Revised: 01/17/2008] [Accepted: 01/25/2008] [Indexed: 10/22/2022]
|
5
|
Jain DS, Subbaiah G, Sanyal M, Jain VK, Shrivastav P. A rapid and specific approach for direct measurement of pravastatin concentration in plasma by LC-MS/MS employing solid-phase extraction. Biomed Chromatogr 2007; 21:67-78. [PMID: 17080507 DOI: 10.1002/bmc.720] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
A rapid, specific and sensitive LC-MS/MS assay using solid-phase extraction (SPE) for the determination of pravastatin, in human plasma is described. The plasma filtrate obtained after SPE, using a polymer base, a hydrophilic-lipophilic balance (HLB) cartridge, was submitted directly to short-column liquid chromatography-tandem mass spectrometric (LC-MS/MS) assay, with negligible matrix effect on the analysis. For validation of the method, the recovery of the free analytes was compared with that from an optimized extraction method, and the analyte stability was examined under conditions mimicking the sample storage, handling, and analysis procedures. The extraction procedure yielded extremely clean extracts with a recovery of 107.44 and 98.93% for pravastatin and IS, respectively. The intra-assay and inter-assay precisions for the samples at the LLOQ were 3.30 and 7.31% respectively. The calibration curves were linear for the dynamic range 0.5-200 ng/mL with correlation coefficient r > or = 0.9988. The intra- and inter-assay accuracy ranged from 95.87 to 112.40%. The method is simple and reliable with a total run time of 3 min. This novel validated method was applied to the pharmacokinetic (PK) study in human volunteers receiving a single oral dose of 40 mg immediate release (IR) formulation.
Collapse
Affiliation(s)
- Deepak S Jain
- Department of Chemistry, School of Sciences, Gujarat University, Navrangpura, Ahmedabad 380 009, India
| | | | | | | | | |
Collapse
|
6
|
Önal A, Sagirli O. Development of a Selective LC Method for the Determination of Pravastatin Sodium. Chromatographia 2006. [DOI: 10.1365/s10337-006-0843-5] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
7
|
Pasha MK, Muzeeb S, Basha SJS, Shashikumar D, Mullangi R, Srinivas NR. Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. Biomed Chromatogr 2006; 20:282-93. [PMID: 16143964 DOI: 10.1002/bmc.561] [Citation(s) in RCA: 65] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
A specific, accurate, precise and reproducible high-performance liquid chromatographic (HPLC) method was developed and validated for the simultaneous quantitation of five 3-hydroxy-3-methyglutaryl coenzyme A (HMG-CoA) reductase inhibitors, viz. atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin, in pharmaceutical formulations and extended the application to in vitro metabolism studies of these statins. Ternary gradient elution at a flow rate of 1 mL/min was employed on an Intertisl ODS 3V column (4.6 x 250 mm, 5 microm) at ambient temperature. The mobile phase consisted of 0.01 m ammonium acetate (pH 5.0), acetonitrile and methanol. Theophylline was used as an internal standard (IS). The HMG-CoA reductase inhibitors and their metabolites were monitored at a wavelength of 237 nm. Drugs were found to be 89.6-105.6% of their label's claim in the pharmaceutical formulations. For in vitro metabolism studies the reaction mixtures were extracted with simple liquid-liquid extraction using ethyl acetate. Baseline separation of statins and their metabolites along with IS free from endogenous interferences was achieved. Nominal retention times of IS, atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin were 7.5, 17.2, 21.6, 28.5, 33.5 and 35.5 min, respectively. The proposed method is simple, selective and could be applicable for routine analysis of HMG-CoA reductase inhibitors in pharmaceutical preparations as well as in vitro metabolism studies.
Collapse
Affiliation(s)
- Md Khalid Pasha
- Drug Metabolism and Pharmacokinetics, Discovery Research, Dr. Reddy's Laboratories Ltd, Miyapur, Hyderabad, India
| | | | | | | | | | | |
Collapse
|
8
|
Nigović B. Electrochemical properties and square-wave voltammetric determination of pravastatin. Anal Bioanal Chem 2005; 384:431-7. [PMID: 16341509 DOI: 10.1007/s00216-005-0188-1] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2005] [Revised: 10/21/2005] [Accepted: 10/21/2005] [Indexed: 11/30/2022]
Abstract
The electrochemical reduction and adsorptive voltammetric behaviour of pravastatin have been studied by means of cyclic and square-wave voltammetry at a hanging mercury-drop electrode in electrolytes of different pH. Within the entire pH range (2.0-9.0) in Britton-Robinson buffer, pravastatin gave rise to a single voltammetric peak in the potential interval from -1.22 to -1.44 V, depending on pravastatin concentration. It was found that the reduction of pravastatin proceeds via a relatively stable intermediate, which is transformed to the final electroinactive product by a coupled chemical reaction or can be re-oxidized back to pravastatin. The rate of chemical transformation is controlled by the proton concentration. The electrode mechanism has the properties of a surface redox reaction. A sensitive analytical method for trace analysis of pravastatin based on the adsorptive stripping technique has been developed. The calibration plot was linear in the range 8x10(-8)-5x10(-7) mol L(-1). Application of the square-wave voltammetric method to determination of pravastatin in a pharmaceutical dosage form, without sample pretreatment, resulted in acceptable deviation from the stated concentration.
Collapse
Affiliation(s)
- Biljana Nigović
- Faculty of Pharmacy and Biochemistry, University of Zagreb, 10000, Zagreb, Croatia.
| |
Collapse
|
9
|
Kircali K, Tunçel M, Aboul-Enein HY. Determination of pravastatin in tablets by capillary electrophoresis. ACTA ACUST UNITED AC 2004; 59:241-4. [PMID: 14987988 DOI: 10.1016/j.farmac.2003.11.006] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2003] [Accepted: 11/20/2003] [Indexed: 10/26/2022]
Abstract
Pravastatin (PRA) is an inhibitor of HMG-CoA reductase enzyme, which is clinically used as a hypolipidemic agent to reduce cholesterol level. A capillary electrophoretic method for the determination of PRA in pharmaceutical tablet formulations is described. PRA and lansoprazole as an internal standard (IS) were well migrated in the background electrolyte of 10 mM borate buffer (pH 8.5) and 10% acetonitrile using a fused silica capillary. The separation was achieved by applying 27.5 kV, detecting at 200 nm and injecting the sample for 0.5 s and with an average migration time (tm) for PRA and IS of 4.7 and 3.9 min, respectively, at ambient temperature. The results were precise and repeatable for areas of the peaks and peak normalization ratio (PNPRA/PNIS). Linearity was found in the concentration range of 1.56-7.78 x 10(-5) M. Intra-day and Inter-day assays were performed and reliable results were obtained. Limit of detection and limit of quantitation were 8 x 10(-6) and 2.4 x 10(-5) M, respectively. The proposed method was successfully applied for the analysis of PRA in the pharmaceutical tablet formulation. The method proved simple, precise and fast since the analysis can be performed in less than 5 min.
Collapse
Affiliation(s)
- Kevser Kircali
- Department of Analytical Chemistry, Faculty of Pharmacy, Anadolu University, Eskisehir 26470, Turkey
| | | | | |
Collapse
|
10
|
Ertürk S, Onal A, Müge Cetin S. Analytical methods for the quantitative determination of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in biological samples. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 793:193-205. [PMID: 12906895 DOI: 10.1016/s1570-0232(03)00314-3] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Published analytical methods for the quantitative determinations of presently available five 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors ("statins"), lovastatin, simvastatin, pravastatin, fluvastatin and atorvastatin, are reviewed for therapeutic drug monitoring purpose in patients. Almost all assay reviewed are based on high-performance liquid chromatography or gas chromatography. Some purification steps (liquid-liquid extraction, solid-phase extraction, etc.) have been used before they are submitted to separation by chromatographic procedures and they are detected by various detection methods like UV, fluorescence and mass spectrometry. This review shows that most method may be used quantitative determination of statins in plasma and they are suitable for therapeutic drug monitoring purpose of these drugs.
Collapse
Affiliation(s)
- Sidika Ertürk
- Istanbul University, Faculty of Pharmacy, Department of Analytical Chemistry, 34116 Istanbul, Turkey.
| | | | | |
Collapse
|
11
|
Zhu Z, Neirinck L. High-performance liquid chromatography coupled with negative ion tandem mass spectrometry for determination of pravastatin in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 783:133-40. [PMID: 12450532 DOI: 10.1016/s1570-0232(02)00526-3] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
A new method, using high-performance liquid chromatography/ion electrospray (negative ion) mass spectrometry, has been developed for the determination of a hydrophilic liver-specific inhibitor of the enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase, pravastatin in human plasma. In this method, plasma samples were prepared by a solid-phase extraction on C(18) Bond Elut cartridge. Chromatography was carried out with a Zorbax C(8) column. Simple isocratic chromatography conditions were used. The method has been validated in a linear range of 0.25-300 ng/ml with a coefficient of variation of 0.6-3.4%. The overall recovery was 90.5% for pravastatin and 90.8% for the internal standard beta-hydroxy-lovastatin. The method is simple and reliable with a total run time of less than 2 min.
Collapse
Affiliation(s)
- Zhimeng Zhu
- Pharmascience, 6111 Royalmount Ave., Suite 100, Quebec, H4P 2T4, Montreal, Canada.
| | | |
Collapse
|
12
|
Toyo’oka T. Fluorescent tagging of physiologically important carboxylic acids, including fatty acids, for their detection in liquid chromatography. Anal Chim Acta 2002. [DOI: 10.1016/s0003-2670(02)00398-7] [Citation(s) in RCA: 54] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
13
|
Applications of immobilized stationary-phase liquid chromatography: a potential in vitro technique. PHARMACEUTICAL SCIENCE & TECHNOLOGY TODAY 2000; 3:406-416. [PMID: 11116200 DOI: 10.1016/s1461-5347(00)00315-1] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Immobilized artificial-membrane chromatography is a potential in vitro technique for determining lipophilicity and studying drug transport and membrane interactions. It is reproducible, efficient and simple. Several other and newer applications of immobilized stationary-phase liquid chromatography have been reported, including the purification of membrane proteins, the synthesis of biomolecules and the simultaneous determination of enzyme activity and enantioselectivity. This article describes the immobilized artificial-membrane concept and provides an overview of the applications, advantages and limitations, in general, of immobilized stationary-phase chromatography.
Collapse
|
14
|
Abstract
Pravastatin, one of the 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) widely used in the management of hypercholesterolaemia, has unique pharmacokinetic characteristics among the members of this class. Many in vivo and in vitro human and animal studies suggest that active transport mechanisms are involved in the pharmacokinetics of pravastatin. The oral bioavailability of pravastatin is low because of incomplete absorption and a first-pass effect. The drug is rapidly absorbed from the upper part of the small intestine, probably via proton-coupled carrier-mediated transport, and then taken up by the liver by a sodium-independent bile acid transporter. About half of the pravastatin that reaches the liver via the portal vein is extracted by the liver, and this hepatic extraction is mainly attributed to biliary excretion which is performed by a primary active transport mechanism. The major metabolites are produced by chemical degradation in the stomach rather than by cytochrome P450-dependent metabolism in the liver. The intact drug and its metabolites are cleared through both hepatic and renal routes, and tubular secretion is a predominant mechanism in renal excretion. The dual routes of pravastatin elimination reduce the need for dosage adjustment if the function of either the liver or kidney is impaired, and also reduce the possibility of drug interactions compared with other statins. which are largely eliminated by metabolism. The lower protein binding than other statins weakens the tendency for displacement of highly protein-bound drugs. Although all statins show a hepatoselective disposition, the mechanism for pravastatin is different from that of the others. There is high uptake of pravastatin by the liver via an active transport mechanism, but not by other tissues because of its hydrophilicity, whereas the disposition characteristics of other statins result from high hepatic extraction because of high lipophilicity. These pharmacokinetic properties of pravastatin may be the result of the drug being given in the pharmacologically active open hydroxy acid form and the fact that its hydrophilicity is markedly higher than that of other statins. The nature of the pravastatin transporters, particularly in humans, remains unknown at present. Further mechanistic studies are required to establish the pharmacokinetic-pharmacodynamic relationships of pravastatin and to provide the optimal therapeutic efficacy for various types of patients with hypercholesterolaemia.
Collapse
Affiliation(s)
- T Hatanaka
- Faculty of Pharmaceutical Sciences, Toyama Medical and Pharmaceutical University, Japan.
| |
Collapse
|
15
|
A comparison of the effects of lovastatin and pravastatin on ubiquinone tissue levels in rats. Curr Ther Res Clin Exp 1998. [DOI: 10.1016/s0011-393x(98)85064-9] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
|
16
|
Carrascal M, Schneider K, Calaf RE, van Leeuwen S, Canosa D, Gelpí E, Abian J. Quantitative electrospray LC-MS and LC-MS/MS in biomedicine. J Pharm Biomed Anal 1998; 17:1129-38. [PMID: 9884202 DOI: 10.1016/s0731-7085(98)00078-8] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The use of electrospray LC-MS and LC-MS/MS for the quantitative determination of two low molecular weight (< 500 Da) organic compounds in human plasma (Lovastatin) and cell supernatants (Arachidonic acid) and medium molecular weight (> 2000 Da) endogenous peptides (Endothelins) in supernatants of human umbilical vein endothelial cell cultures is reported. These methods make use either of deuterium labelled or structurally similar molecules as internal standards for quantitation and one or more pre-purification steps previous the LC-MS analysis. Linear calibration curves and detection limits around 50 pg ml(-1) were obtained in all three cases.
Collapse
Affiliation(s)
- M Carrascal
- Department of Medical Bioanalysis, IDIBAPS, IIBB-CSIC, Barcelona, Spain
| | | | | | | | | | | | | |
Collapse
|
17
|
Desager JP, Horsmans Y. Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Clin Pharmacokinet 1996; 31:348-71. [PMID: 9118584 DOI: 10.2165/00003088-199631050-00003] [Citation(s) in RCA: 135] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase is the key enzyme of cholesterol synthesis. HMG-CoA reductase inhibitors are potent reversible inhibitors of this enzyme, which act by competing for the substrate HMG-CoA. This review is mainly devoted to the 4 main HMG-CoA reductase inhibitors used today: lovastatin, simvastatin, pravastatin and fluvastatin. Depending upon the dosage, these drugs are able to reduce plasma cholesterol levels by more than 40%. After absorption, each undergoes extensive hepatic first-pass metabolism. Up to 5 primary metabolites are formed, some of which are active inhibitors. The elimination half-lives vary from 0.5 to 3.5 hours and excretion is mainly via the faeces. A limited number of drug interactions has been reported. Increases in liver enzymes and muscle creatine kinase activity are among the most severe adverse effects. These powerful drugs should be reserved for patients with high plasma cholesterol levels and/or those with cardiovascular disease. New therapeutic approaches to atherosclerosis are currently under investigation. HMG-CoA reductase inhibitors are the cornerstone of this research.
Collapse
Affiliation(s)
- J P Desager
- Departement de Médecine Interne, Université Catholique de Louvain, Brussels, Belgium
| | | |
Collapse
|
18
|
Toreson H, Eriksson BM. Determination of fluvastatin enantiomers and the racemate in human blood plasma by liquid chromatography and fluorometric detection. J Chromatogr A 1996; 729:13-8. [PMID: 9004934 DOI: 10.1016/0021-9673(95)00897-7] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Liquid chromatographic methods for the determination of fluvastatin, as racemate and as separated enantiomers, are described. Fluvastatin was extracted at pH 6.0 from blood plasma into methyl tert.-butyl ether. The organic phase was evaporated and the extract redissolved into either a phosphate buffer solution of pH 6.0 containing tetrabutylammonium fluoride and methanol for the racemate determination, or in a mixture of acetonitrile and water for assaying the enantiomers. The absolute recoveries were 95 and 86% for the racemate and the enantiomers, respectively, and the limit of quantitation 0.5 nmol/1 for the racemate, and 5 nmol/l for the enantiomers, when using half a millilitre of plasma sample. The samples were chromatographed on a C8 column (racemate) and on a Chiralcel OD-R column (enantiomers), and monitored using fluorescence detection. In the achiral system, post-column exposure of the eluate to UV light enhanced the sensitivity by 4 to 5 times when compared with analysis based on the native fluorescence.
Collapse
|